Travere reports Q3 net income of $25.7M; FILSPARI sales up 155% YoY to $90.9M

Travere Therapeutics, Inc.

2025-Q3 EPS reported -$0.32 vs consensus -$0.21 ▼ miss (-50.9%)

U.S. FILSPARI net product sales $90.9M (+155% YoY); 731 new patient start forms in Q3.
Total revenue $164.9M incl. $40M milestone from CSL Vifor; net income $25.7M ($0.29 basic EPS) vs net loss of $54.8M in Q3 2024.
Remaining $68.9M of 2025 convertible notes retired; cash & equivalents $254.5M as of Sep 30 (excl. October milestone).
FDA sNDA for FILSPARI in FSGS under review; PDUFA target Jan 13, 2026; no advisory committee needed.
REMS modified removing embryo-fetal toxicity monitoring; KDIGO guidelines recommend FILSPARI as first-line therapy in IgAN.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.